On May 11, 2026, Hims & Hers Health (NYSE: HIMS) reported first quarter 2026 financial results that missed analyst expectations on both the top and bottom lines, sending the telehealth platform's stock down roughly 13% in extended-hours trading on May 12. Revenue grew 4% year-over-year to $608.1 million, below the consensus $616.85 million estimate; the company posted a per-share loss of $0.40, compared with consensus expectations of $0.03 EPS in positive territory. Net loss of $92 million widened from $50 million in Q1 2025, and adjusted EBITDA of $44 million fell from $91 million in the year-earlier quarter.

Why It Matters

Hims & Hers is the publicly-traded bellwether for the entire DTC male-sexual-health-telehealth segment, and a 13% drop on a Q1 miss is the clearest market signal in eighteen months that the category has matured past its hypergrowth phase. The raised full-year guidance shows management still sees the year through to GLP-1 distribution scale, but the gross-margin compression to 65% is the metric to watch — it tells you whether telehealth as a distribution model has durable unit economics in a branded-drugs world or has been quietly subsidizing growth on the compounded side. The Q2 print, due in early August, will be the first quarter with clean Novo Nordisk economics and the first real test of the new model.

The story behind the numbers is the company's ongoing pivot away from compounded GLP-1 medications, which had been the marginal growth engine in 2024–2025 before FDA enforcement on compounded semaglutide forced a strategic reset. Gross margin compressed to 65% from 73%, reflecting restructuring costs from winding down compounded GLP-1 inventory and the higher cost-of-goods on branded Wegovy and Ozempic sourced through the company's March 2026 Novo Nordisk partnership (covered in this archive's hims-novo-nordisk-glp1-partnership story). Subscribers grew 9% to nearly 2.6 million, indicating the customer base remains stable even as average revenue per subscriber softens during the product mix transition.

Management raised full-year 2026 guidance despite the Q1 miss, projecting revenue of $2.8–$3.0 billion and adjusted EBITDA of $275–$350 million. Several analyst notes interpreted the raise as a signal that the Novo Nordisk distribution ramp and a similar (unannounced) Eli Lilly weight-loss partnership are expected to begin meaningfully contributing in the second half. Investor commentary on the post-earnings call focused on whether Hims's increasingly diversified product mix — covering ED, hair loss, mental health, dermatology, women's health, and weight management — is a "Netflix of healthcare" platform thesis or a margin trap as each new vertical demands its own logistics, regulatory work, and supply contracts.

For the sex tech and male sexual health segments specifically, the Q1 results have a narrower read: Hims's ED business remains a stable revenue anchor and its subscriber growth (+9%) is more disciplined than the explosive 2022–2024 period, suggesting the easy customer-acquisition gains in telehealth ED are over. New entrants targeting the same demographic — Eddie by Giddy, Mojo, Aspargo's liquid sildenafil — should expect a slower-growth, margin-pressured market rather than the hypergrowth conditions that made Hims a unicorn.

Sources

Update — 2026-05-14

Initial entry — story first created.

Update — 2026-05-25

The insider selling picture has gotten uglier. 24/7 Wall Street reported on May 18 that CEO Andrew Dudum sold 436,190 shares at $24.77 on April 13 — nearly a month before the earnings release — and the CFO, COO, and Chief Legal Officer all dumped stock in the weeks preceding the report. The stock has now fallen 54.66% over the trailing twelve months. On May 24, the Washington Post published a profile framing the company's strategic pivot away from its sexual health roots toward "wellness and longevity," positioning Hims as a "technology intermediary" rather than a compounder of copycat drugs. The company is now integrating telehealth, electronic medical records, digital prescriptions, cloud pharmacy fulfillment, and personalization across weight loss, hormone health, dermatology, mental health, and sexual wellness. For the sex tech industry, the signal is clear: the most visible publicly traded company in male sexual health is diversifying away from the category that built it.

New Sources

Update — 2026-05-26

Hims & Hers announced on May 18, 2026 a proposed private offering of $300 million in convertible senior notes due 2032, subsequently upsized to $350 million at 0.00% interest. Net proceeds will fund the company's international expansion strategy — including its proposed acquisition of Australian telehealth platform Eucalyptus, expected to close mid-2026 — and investments in technology, fulfillment infrastructure, and AI capabilities. The company also arranged capped call transactions to limit potential dilution. The zero-coupon structure is aggressive: it signals management's confidence in future cash generation but adds $350M in debt to a balance sheet already absorbing the Novo Nordisk partnership economics and post-GLP-1 transition costs. HIMS stock fell approximately 7% on the announcement.

New Sources